Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant WIDER: Ribociclib + Endocrine Therapy in HR+/HER2- Early Breast Cancer
NCT05827081Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2024
- Primary completion
- Sep 2029
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Novartis. Primary endpoint: Invasive Breast Cancer Free Survival at 3 years. Started Feb 2024; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05827081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827081.